Meet IceCure at the largest radiology conference, RSNA, USA, Dec 2-4th, 2019

Schedule a meeting on Dec 2-4th with the IceCure Management, CEO, Eyal Shamir and VP Biz Dev & Marketing, Tlalit Bussi Tel Tzure at the Radiological Society of North America (RSNA) 2019, Dec 2-4th. Meet with us to learn the latest in our clinical research using the Prosense cryoablation system in interventional radiology.  To confirm […]

Meet IceCure at leading medical device exhibition, MEDICA, Germany 2019

Schedule a meeting with our very own Biz Dev and Marketing Manager, Tlalit Bussi at MEDICA 2019.  Join her to discuss potential new partnerships and learn more about how our LN2 cryoablation system, ProSense, is helping transform cancer treatment, without the need for surgery! To schedule a meeting, please email

IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval

The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement comes hot on the back of the company receiving a Class 3 CPT code from the American Medical Association that enables providers to apply for reimbursement for procedures using cryoablation […]